Research summary, original research, 2002

Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure

Preston DL, Ron E, Yonehara S, Kobuke T, Fujii H, Kishikawa M, et al.. Journal of the National Cancer Institute. 2002

Read the original paper

In plain language

Among 80,160 atomic bomb survivors, nervous system tumor incidence rose linearly with radiation dose, most strongly for schwannoma. This is an association from acute exposure and does not directly measure risk from the fluoroscopy team's chronic low-dose exposure.

At a glance

Type of study
Original research, Prospective cohort study
Who was studied
General population
Size
n = 80,160 atomic bomb survivors
Where
Japan
Summary based on
the abstract

What it found

  • There was a statistically significant dose-related excess of all nervous system tumors combined.

    Key figures: ERR(Sv) = 1.2, 95% confidence interval [confidence interval (CI)] = 0.6 to 2.1

  • Schwannoma showed the highest excess relative risk per sievert.

    Key figures: 4.5, 95% CI = 1.9 to 9.2

  • All other nervous system tumors as a group also had significantly elevated risk. Increases for meningioma, glioma and pituitary tumors were not statistically significant.

    Key figures: ERR(Sv) = 0.6, 95% CI = 0.1 to 1.3

  • Dose-response relationships were linear. The authors conclude that moderate doses below 1 Sv are associated with elevated tumor incidence.

    Key figures: <1 Sv

  • For nervous system tumors other than schwannoma, excess risks were higher in men and in those exposed during childhood.

Limits to keep in mind

Survivors had an acute, high-dose-rate, whole-body exposure, which differs from the chronic, low-dose, partial-body occupational exposure of fluoroscopy staff. Several tumor-specific estimates have wide confidence intervals that include no effect.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.